# US 2018/0022722 A1 · Compounds for Stabilizing Ryanodine Receptors from Aberrant Levels of Calcium Release

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022722 A1
- Document ID: US20180022722A1
- Status: Published application
- Kind: A1
- Application number: 15/671,833
- Filed: 2017-08-08
- Published: 2018-01-25
- Earliest claimed: 2013-03-15
- Assignees: Rosalind Franklin University of Medicine and Science
- Applicants: Rosalind Franklin University of Medicine and Science
- Inventors: Grace E. Stutzmann; Russell Dahl; Christopher H. Kaiho
- Web page: https://patentgrep.com/patent/US20180022722A1

## CPC

- C07D 307/54: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A method for normalizing neuronal calcium dyshomeostasis in a subject in need thereof comprising administering to the subject and effective amount of the compound selected from the group consisting of:
and a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subject is a human subject.

### Claim 34

A method for treating a neurological or neurodegenerative disorder in a subject comprising administering to the subject an effective amount of the compound
and a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the neurological or neurodegenerative disorder is Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, or an aging-related CNS disorder.

### Claim 36 (depends on 35)

The method of claim 35, wherein the neurological or neurodegenerative disorder is Alzheimer's disease.